189 related articles for article (PubMed ID: 28853334)
1. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.
Liu X; Jing Z; Jia WQ; Wang SQ; Ma Y; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Aug; 36(11):2988-3002. PubMed ID: 28853334
[TBL] [Abstract][Full Text] [Related]
2. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations.
Feng XY; Jia WQ; Liu X; Jing Z; Liu YY; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():178-189. PubMed ID: 30557816
[TBL] [Abstract][Full Text] [Related]
4.
Feng XY; Ding TT; Liu YY; Xu WR; Cheng XC
J Biomol Struct Dyn; 2021 Mar; 39(5):1853-1864. PubMed ID: 32189570
[TBL] [Abstract][Full Text] [Related]
5. Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors.
Zhang LS; Wang SQ; Xu WR; Wang RL; Wang JF
PLoS One; 2012; 7(10):e48453. PubMed ID: 23119024
[TBL] [Abstract][Full Text] [Related]
6. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.
Liu L; Ma Y; Wang RL; Xu WR; Wang SQ; Chou KC
Drug Des Devel Ther; 2013; 7():279-88. PubMed ID: 23630413
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel PPARα/γ Dual Agonists by Virtual Screening of Specs Database.
Zhang J; Liu X; Wang SQ; Fu JW; Xu WR; Cheng XC; Wang RL
Comb Chem High Throughput Screen; 2016; 19(8):644-655. PubMed ID: 27316369
[TBL] [Abstract][Full Text] [Related]
8. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
9. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
dos Santos JC; Bernardes A; Giampietro L; Ammazzalorso A; De Filippis B; Amoroso R; Polikarpov I
J Struct Biol; 2015 Sep; 191(3):332-40. PubMed ID: 26185032
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
[TBL] [Abstract][Full Text] [Related]
11. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OA
Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
[TBL] [Abstract][Full Text] [Related]
12. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications.
Mandal S; Faizan S; Raghavendra NM; Kumar BRP
Mol Divers; 2023 Dec; 27(6):2605-2631. PubMed ID: 36437421
[TBL] [Abstract][Full Text] [Related]
14. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
[TBL] [Abstract][Full Text] [Related]
16. Virtual identification of novel PPARα/γ dual agonists by 3D-QSAR, molecule docking and molecular dynamics studies.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
J Biomol Struct Dyn; 2020 Jun; 38(9):2672-2685. PubMed ID: 31418313
[TBL] [Abstract][Full Text] [Related]
17. Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar.
Jia WQ; Jing Z; Liu X; Feng XY; Liu YY; Wang SQ; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Oct; 36(13):3496-3512. PubMed ID: 29081262
[TBL] [Abstract][Full Text] [Related]
18. In silico and in vitro analysis of PPAR - α / γ dual agonists: Comparative evaluation of potential phytochemicals with anti-obesity drug orlistat.
Mandal SK; Kumar BK; Sharma PK; Murugesan S; Deepa PR
Comput Biol Med; 2022 Aug; 147():105796. PubMed ID: 35809408
[TBL] [Abstract][Full Text] [Related]
19. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
